We are live on ! Find out more
CASI

CASI Pharmaceuticals

Delisted

CASI was delisted on the 25th of February, 2026.

58 hedge funds and large institutions have $44.4M invested in CASI Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

9% more funds holding

Funds holding: 5358 (+5)

0.07% more ownership

Funds ownership: 2.12%2.2% (+0.07%)

30% less capital invested

Capital invested by funds: $63.2M → $44.4M (-$18.8M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
58
Holders Change
+5
Holders Change %
+9.43%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
21
Reduced
15
Closed
4
Calls
Puts
Net Calls
Net Calls Change

CASI Hedge Fund Activity: Q1 2020 in Review

58 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2020, worth a combined $44.4M — down 30% from $63.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CASI positions and 4 closed out — a net gain of 7 holders — while 21 added to existing stakes and 15 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.48M. The largest seller was State of Wisconsin Investment Board, exiting entirely with an estimated $213K sold.

  • 58 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2020, up from 53 in Q4 2019.
  • Funds reported $44.4M of CASI Pharmaceuticals stock for Q1 2020, down 30% quarter-over-quarter.
  • 11 funds opened new CASI Pharmaceuticals positions in Q1 2020 and 4 closed out, a net change of +7 holders.
  • The largest CASI Pharmaceuticals buyer in Q1 2020 was Ikarian Capital, an estimated $2.48M added.
  • The largest CASI Pharmaceuticals seller in Q1 2020 was State of Wisconsin Investment Board, an estimated $213K sold.

Based on aggregated 13F filings for Q1 2020.